Skip to main content

EQ

Stock
Health Care
Biotechnology

Performance overview

EQ Price
Price Chart

Forward-looking statistics

Beta
0.93
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Company info

SectorHealth Care
IndustryBiotechnology
Employees46
Market cap$28.2M

Fundamentals

Enterprise value-$2.9M
Revenue$30.4M
Revenue per employee—
Profit margin-46.00%
Debt to equity2.79

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.39
Dividend per share—
Revenue per share$0.86
Avg trading volume (30 day)$790K
Avg trading volume (10 day)$140K
Put-call ratio—

Macro factor sensitivity

Growth+4.3
Credit+3.1
Liquidity-3.1
Inflation+0.8
Commodities+1.6
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio-0.25
Price to sales0.38
P/E Ratio-0.25
Enterprise Value to Revenue-0.10
Price to book1.08

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day—
Ex. dividend day—

News

Equinix (EQIX) Rises Higher Than Market: Key Facts

Equinix (EQIX) reached $789.19 at the closing of the latest trading day, reflecting a +1.47% change compared to its last close.

Zacks Investment Research (July 21, 2025)
Final Trades: Morgan Stanley, Netflix, Cognex and EQT Corp.

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (July 21, 2025)
Here's Why You Should Add Equity Residential Stock to Your Portfolio

EQR leverages high occupancy, tech adoption and a resilient rental market to fuel growth and long-term dividend gains.

Zacks Investment Research (July 18, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free